Clinical Practice Snapshot: Incorporating Janus Kinase Inhibitors Into the Management of Rheumatoid Arthritis
Clinical Practice Snapshot: Incorporating Janus Kinase Inhibitors Into the Management of Rheumatoid Arthritis is organized by Global Academy For Medical Education and will be held Oct 01, 2017 - Oct 31, 2018. This CME Conference has been approved for a maximum of 1.00 AMA PRA Category 1 Credits.
Course Description :
Current guidelines for the management of rheumatoid arthritis (RA) address the concern that many patients fail to respond, or lose response, to first-line therapy with disease-modifying antirheumatic drugs (DMARDs). Lack of understanding about the optimal use of avail- able RA therapies—including combination therapy or switching to other drugs within a class or in a different class—means that many patients may fail to achieve remission (the ideal goal) or minimal levels of disease activity. Clinicians who are unaware of current practice guidelines may not be providing optimal management for their patients with RA. In addition, clinicians should be aware of data concerning the safety and efficacy of newly available drugs so as to ensure selection of optimal therapies for patients with RA. Knowledge of agents that have novel mechanisms of action, including Janus kinase inhibitors, can improve clinicians’ confidence when switching therapies in patients who have suboptimal response despite appropriate use of DMARD therapies.
At the conclusion of this activity, the participant will be able to:
• Design optimal treatment strategies for patients with rheumatoid arthritis (RA) to improve remission rates and/or minimize levels of disease
• Recognize the role that Janus kinase (JAK) plays in the pathogenesis of RA and the corresponding impact of JAK inhibition in the management of RA
• Discuss treatment options for RA, including the use of JAK inhibitors, as reflected in current practice guideline
Additional details will be posted as soon as they are available.